ZUBIQO.
AI & MLCryptoFinanceBig TechAI Models
CybersecurityGamingEVs & Clean EnergyRoboticsAerospaceBiotech & HealthConsumer Hardware
Enterprise
ZUBIQO.

High-magnitude intelligence briefs for the tech and finance sectors. Zero fluff. Maximum signal.

contact@zubiqo.com
X (Twitter)ThreadsTelegramBlueskyMastodon

Sections

  • AI & ML
  • Crypto
  • Finance
  • Big Tech
  • Cybersecurity
  • Gaming
  • EVs & Clean Energy
  • Robotics
  • Aerospace
  • Biotech & Health

Publication

  • Evening Newsletter
  • About Us
  • Editorial Ethics
  • Partner With Us
  • Contact Us

Tools

  • AI Models Pricing

Legal

  • Privacy Policy
  • Terms of Service
  • Fair Use & DMCA

Disclaimer:Zubiqo Intelligence operates as an automated technology and market intelligence publication providing AI-assisted synthesis with source attribution. The news briefs, market analysis, “Magnitude Scores”, and “Community Sentiment” metrics provided on this platform are strictly for informational and educational purposes only. They do not constitute financial, legal, investment, or trading advice. Cryptocurrencies and financial markets are highly volatile; always conduct your own research and consult with a licensed professional before making any investment decisions. By using this site, you agree to our Terms of Service.

© 2026 Zubiqo Intelligence. All rights reserved.

Search Intelligence

Results for: "research"(123 total found)

Microsoft Drops Open-Source Agent Hitting 92.1% Test Completion
AI
2 months ago•1 min read

Microsoft Drops Open-Source Agent Hitting 92.1% Test Completion

Zubiqo Take

“Generic AI tools fail at testing because they ignore repository context, so enforcing a strict research-plan-implement workflow is the only way you don't end up manually fixing broken builds.”

AI: BullishMag 7
MarkTechPost
Emergent BioSolutions Axes Top R&D Role and Cuts 93 Jobs in Restructuring Pivot
Finance
3 months ago•2 min read

Emergent BioSolutions Axes Top R&D Role and Cuts 93 Jobs in Restructuring Pivot

Zubiqo Take

“Merging medical research under the chief growth officer proves the company is abandoning expensive in-house scientific discovery to focus purely on acquiring external assets and squeezing profit from its existing biodefense portfolio.”

AI: BearishMag 6
Fierce Biotech
AstraZeneca Stock Drops Following Rumored $400 Billion Bristol Myers Squibb Merger
Urgent
Finance
3 months ago•1 min read

AstraZeneca Stock Drops Following Rumored $400 Billion Bristol Myers Squibb Merger

Zubiqo Take

“Pharma megamergers don't create innovation, they just create massive integration headaches and cut research budgets.”

AI: BearishMag 10
Yahoo Finance